Market Access Deal finally unlocks NHS access to ITF’s Duchenne drug PharmaphorumAfter nearly two years of wrangling, ITF's Duvyzat can be used by the NHS to treat people living with Duchenne muscular dystrophy.Rare DiseaseRead full story pharminent May 11, 2026 (Last updated: May 11, 2026) Pharmaphorum After nearly two years of wrangling, ITF’s Duvyzat can be used by the NHS to treat people living with Duchenne muscular dystrophy. Rare Disease Read full story Post navigation Previous: BMS’ Sotyktu secures EC approval for psoriatic arthritisNext: Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher Related Stories Market Access How cost and perception could reshape the GLP-1 market pharminent August 21, 2026 Market Access D.C. Circuit Affirms HHS Authority Over 340B Rebate Models pharminent July 24, 2026 Market Access NICE aims to cut funding for Amgen lung cancer drug Lumykras pharminent July 9, 2026
